Pulmonary arterial hypertension (PAH), a condition that is defined by pulmonary vasculature constriction and remodeling, involves dysfunctional signaling of the serotonin (5-HT) receptors, 5-HT 2A/2B/7 . In a rat model of monocrotaline (MCT)-induced PAH, the effectiveness of RP5063 (RP), a dopamine and 5-HT receptor modulator, was evaluated as monotherapy and as an adjunct to standard PAH treatments. After a single 60 mg/kg dose of MCT, rats received vehicle (MCT+Veh; gavage twice-daily [b.i.d.]), RP (10 mg/kg; gavage b.i.d.), bosentan (B; 100 mg/kg; gavage BID), sildenafil (S; 50 mg/kg; gavage, BID), treprostinil (T; 100 ng/kg/min over 24 h intravenous), RP+B, RP+S, and RP+T for 28 days. Single-agent RP limited the functional and structural effects of PAH seen in the MCT+Veh group, with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO 2 , and pulmonary blood vessel structural changes. These effects appeared comparable with those associated with B, S, and T. Adjunctive RP treatment resulted in significantly lower mean pulmonary arterial pressures, RV systolic pressure. It also improved SO 2 measurements, as compared with MCT+Veh (P < 0.05), and diastolic pulmonary artery pressure (P < 0.05), as compared with single-agent B and S therapy (Bonferroni method adjusting for multiplicity). RP+S appeared to show the most consistent and extensive effects on pulmonary hemodynamics, respiratory parameters, and histopathologic changes. These results corroborate earlier preclinical findings supporting the efficacy of single-agent RP in PAH. RP, as mono and adjunctive therapy compared with induced-control, mitigated the functional and structural effects of MCTinduced PAH.
Introduction
Pulmonary arterial hypertension (PAH) is a chronic, debilitating condition with a prevalence ratio of up to 1: 20,000 (Frumkin, 2012; Peacock et al., 2007) . This rare disorder involves increased pulmonary vascular resistance leading to right ventricular (RV) failure and death (Frumkin, 2012) .
Present management involves monotherapy or combination therapy with drugs that: (1) inhibit phosphodiesterase-5; (2) block endothelin receptors; and/or (3) deliver exogenous prostacyclins or analogs (Corbin et al., 2005; Christman et al., 1992; Galie et al., 2004; Humbert et al., 2004a , 2004b , McLaughlin et al., 2009 . Unfortunately, these approaches fall short of limiting the ongoing cytoproliferative processes that lead to pulmonary vascular structure modification and disease progression (Zopf et al., 2011) . With only one-half of patients surviving between 5 and 7 years, significant need exists for new therapeutic strategies (Benza et al., 2012) .
Multiple drug combinations have been used in PAH management, dictated by the progression of the disease. One retrospective analysis reported that 56% of patients were taking at least one additional medication within 2 years of their initial diagnosis, in addition to the initial treatment (Provencher et al., 2006) . However, given that currently targeted pathways can overlap, co-administration has yielded inconsistent results clinically (Gruenig et al., 2009; Galiè et al., 2009 ).
Thus, new approaches are needed to address pulmonary vascular tone and to prevent those underlying processes that influence PAH development, progression, and mortality.
Serotonin (5-HT) is a factor that contributes to the pathogenesis of PAH, as pulmonary arteries express 5-HT 1B/2A/2B/7 receptors (Esteve et al., 2007; MacLean and Dempsie, 2010; Shacham et al., 2006; West et al., 2016) . In the pulmonary circulation, 5-HT can activate 5-HT 2A/ 2B/7 receptors and the 5-HT transporter (SERT) in the vascular smooth muscle (VSM) (Dumitrascu et al., 2011; Jähnichen et al., 2004) . These actions lead to constriction and proliferation of pulmonary VSM cells (Zopf et al., 2011) . Agents that antagonize 5-HT 2B have been reported to be effective in treating experimental PAH in rodents (West et al., 2016) .
RP5063 (RP) is a multimodal dopamine (D)-5-HT stabilizer with partial agonist activity for D 2/3/4 and 5-HT 1A/2A , antagonist activity for 5-HT 2B/2C/6/7, and moderate affinity for the SERT (Cantillon et al., 2017) . Initial preclinical studies in rats demonstrated single-agent RP to be effective in PAH. In a monocrotaline (MCT) model, twice daily (b.i.d.) 10 mg/kg RP produced functional improvements in pulmonary hemodynamics and the Fulton Index. As compared with with sildenafil (S) at 50 mg/kg, b.i.d., RP also favorably altered the structural composition and smooth muscle wall thickness in the pulmonary vascular system and suppressed inflammatory cytokines. In a Sugen 5416-hypoxia (SuHx) model, RP dosed at 10 and 20mg/kg b.i.d. showed functional improvements in pulmonary hemodynamics and respiratory parameters. It also lowered the percentage of muscular vessels, limited arterial obliteration from endothelial cell proliferation, prevented plexiform lesions, and stemmed leukotriene-B4 (LT-B4) release.
To build on the single-agent efficacy of RP in experimental models of PAH in rats, the present study was designed to assess the efficacy of RP at 10 mg/kg, alone and co-administrated with S, bosentan (B), and treprostinil (T) in the MCT-induced PAH rat model.
Materials and methods

Experimental design
In this parallel-design study, 90 male Wistar-Kyoto rats (weights: 200-250 g; ages: 10-12 weeks; Charles River Laboratories, St Constant, Quebec, Canada) were randomized according to their body weight into 9 experimental groups: 8 groups of 10 (MCT-induced) and 1 group (non-induced) of 10. The study schedule was such that an equal number of animals per treatment group were monitored and processed on each terminal surgery day.
The institutional animal ethics committee of IPS Therapeutique (IPST) approved the study in accordance with the principles of the Canadian Council on Animal Care (CCAC). IPST identified, housed, and cared for the animals per the CCAC guidelines.
On Day 0, dimethyl sulfoxide (DMSO; Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) solution (0.5 ml) was injected into 10 healthy animals in Group 1, and MCT solution (25 mg/ml diluted in DMSO) dosed at 60 mg/kg was administered to 80 animals, divided into Groups 2-9, with each group consisting of 10 animals. Treatments in Groups 2-9 were initiated on Day 0 and continued until Day 27. During this period, rats in Groups 2-7 were administered twice daily [b.i.d.] via oral gavage one of the following: (1) Group 2 (5% glucose solution; IPST, Sherbrooke, Quebec, Canada) as the negative control; (2) Group 3, RP (Reviva Pharmaceuticals, Inc. Batch GP13DPBF01), dosed at 10 mg/kg; (3) Group 4, B (Sigma-Aldrich Canada Ltd.), dosed at 100 mg/kg; (4) Group 5, B+RP; (5) Group 6, S (Sildenafil mesylate salt, Genemed Synthesis Inc., San Antonio, TX) 50 mg/kg; (6) Group 7, S +RP. In the last two groups, T (Adooq Bioscience, Inc., Irvine, CA), dosed at 100 ng/kg/min over 24 h, as a single agent in Group 8 and in combination with RP dosed b.i.d. via oral gavage in Group 9. RP was prepared by dissolving 1500 mg of active drug into 2 L of sterile 5% glucose solution, resulting in solution 0.75 mg/ml. B was formulated daily with 1200 mg in 96 ml of distilled sterile water (ISPT) resulting in a solution of 12.5 mg/ml. S was prepared with 3500 mg of active drug dissolved in 923 ml of sterile 5% glucose solution to obtain a solution of 3.79 mg/ml. T was formulated with 35 ml of 0.595 mg/ml solution of active drug in sterile saline to deliver 100 ng/kg/min based on a 250 g body weight rat for a period of 28 days for a total of 1 mg. Alzet 2 ML4 pumps (ALZET Osmotic Pumps, Cupertino, CA) were used for delivery, dispensing a volume of 2 ml and at a delivery rate of 2.5 µg/h. Animals assigned to this group were anesthetized with a mixture of 2-2.5% isoflurane (United States Pharmacopeia, USP) in 100% O 2 one day prior to the chronic hypoxia induction for the implantation of the treprostinil-filled min-osmotic pump Alzet subcutaneously in the dorsal skin flap.
During the treatment period, rats were given food and water ad libitum. They were observed daily for behavior and general health status, and had blood samples, body weights, and body temperatures taken weekly.
On Day 28, the animals were anesthetized with a mixture of 2-2.5% isoflurane USP (Abbott Laboratories, Montreal, Canada) in 100% O 2 , and placed on a heating pad to maintain body temperature. Rats were then tracheotomized and immediately ventilated by means of a positive-pressure rodent respirator SAR830P (CWE Inc., Ardmore, PA USA) set at~10 ml/kg body weight at a frequency of 90 strokes/min. Lead II electrocardiogram (ECG) needle electrodes were introduce under the skin of the rat to continuously monitor the ECG during surgical procedure. A cannula connected to a pressure transducer was inserted into the left femoral artery to measure SAP. The heart was exposed through a sternotomy and a 20 G 1.16-in. Insyte catheter was introduced into the RV and rapidly hooked up to a saline filled PR-50 catheter connected to a pressure transducer. Hemodynamic parameters were recorded continuously for at least 5 min or until loss of quality in the pulmonary arterial pressure (PAP) signal. These recordings involved moving a flexible catheter attached to a pressure transducer from the RV cavity, through the pulmonary valve, into the pulmonary artery and observing the clear transitions in diastolic pressures and general pressure waveforms, as the catheter transitioned from the ventricle into the artery. At the end of the recording, a blood sample was collected. After the animal was exsanguinated, the pulmonary circulation was flushed with 0.9% NaCl, and tissues were harvested for further analysis.
Parameters measured on surgery day
On Day 28, a variety of parameters were obtained. Cardiac activity was monitored using electrocardiographic (ECG) contact electrodes (Harvard BioSciences Inc., Holliston, MA) placed in a lead-I/II configuration and connected to an IsoDam8 differential amplifier (World Precision Instruments, LLC, Sarasota, FL). Heart rate (HR) was recorded using duplicate systems: (1) from the ECG records (RR-intervals); and (2) by using an N-595 pulse oximeter (Nonin, Plymouth, MN) attached to the left front paw of the animal. Blood oxygen saturation was measured using a pulse oximeter (Nonin) signal attached to the left front paw of the animal.
Systemic arterial blood pressure (SAP) was monitored using an intra-arterial, fluid-filled catheter connected to a pressure transducer (AD Instruments, Colorado Springs, CO), with diastolic and systolic pressures values measured in mmHg using the Clampfit 10.2.0.14 (Axon Instrument Inc., Foster City, CA [now Molecular Devices Inc.]). Calculation of mean SAP (mSAP) and pulse pressure involved the following formulas: (1) mSAP = diastolic pressure + ([systolic pressurediastolic pressure] / 3); and (2) pulse pressure = systolic pressurediastolic pressure RV systemic pressure (RVSP) and PAP were measured using an intra-ventricular, fluid-filled catheter connected to a pressure transducer (AD Instruments, Colorado Springs, CO). Diastolic and systolic pressures were measured in mmHg using Clampfit 10.2.0.14 readings. Calculation of mean RVSP (mRVSP) and mean PAP (mPAP) was as described for mSAP. All hemodynamic parameters were digitized using Digidata 1440A interface (Axon Instrument, Inc.) and acquired displayed using Axoscope 10.2.0.14 (Axon Instrument, Inc.).
All respiratory parameters were monitored and extracted from the SAR830P. These were digitized using Digidata 1440 interface (Axon Instrument, Inc.) and the acquired results were displayed using Axoscope 10.2.0.14 (Axon Instrument, Inc.).
Organ weights were expressed as relative percentages and were calculated as follows: Relative organ weight = (organ weight × 100) / body weight. Fulton index (RV / Left Ventricle (LV) + Septum [LV+S]) ratio was calculated as such: Fulton index = RV weight / LV+S weight).
Histologic preparation and categorization
Trachea, lungs, and heart were removed together; the liver was extracted separately. All tissues were weighed, including the right and left lobes of the lung, as well as the wet weights of the RV and LV+S of the heart. All tissues were fixed in 10% neutral buffered formalin (NBF).
A transversal section of the middle left lobe was cut and forwarded in 10% NBF to the Institute for Research in Immunology and Cancer (Montreal, Quebec, Canada). Tissue were embedded, sliced (5-µm thickness), mounted, and conventionally stained with hematoxylin and eosin. Tissue on the glass slide was then visualized at 200 × magnification (Eclipse T100 microscope, Nikon, Melville, NY). At least 15 nonoverlapping view fields/lung were selected for microphotographs (Nikon DS-Fi1 digital camera with Nikon NIS Elements 4.30, Nikon).
All vessels in a tissue section were analyzed, from largest to smallest, with no threshold or limit set in vessel size. Intra-acinar vessels were included. Vessels associated with terminal bronchioles and all larger airways were excluded. Vessels were divided based on lumen diameter: (1) small (10-50 µm); (2) medium (50-100 µm); and (3) large (>100 µm). Vessels were categorized based on muscularity: (1) complete, defined as coverage greater than 90% circumference surrounded by a smooth muscle layer; (2) partial, defined as coverage between 10% and 90% circumference surrounded by a smooth muscle layer, along with a crescent of smooth muscle and 2 elastic laminae for part of the circumference; and (3) non-muscular, defined by a single elastic lamina for the entire circumference (<10%) of the vessel with no apparent smooth muscle layer.
Statistics
Values were presented as means ± standard error of means (S.E.M.). Repeated unpaired Student t-tests using Excel 2007 (Microsoft, Redmond, WA) were used to compare experimental conditions. Comparisons included: (1) MCT+Veh (Group 2) versus non-induced healthy animals (No-MCT; Group 1) to confirm the successful induction of the disease; and (2) Treatment (Groups 3-9) versus MCT+Veh (Group 2) to assess the efficacy of the treatments. Differences were considered significant when P ≤ 0.05. Efficacy of RP co-administered with bosentan, sildenafil or treprostinil versus single agent were tested using one-way analysis of variance with a Bonferroni multiplicity adjustment for the 3 comparisons using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA). Excel 2007 was also used to graph results.
Results
Animal disposition
Of the 90 animals randomized, 80 had completed the 28-day course of the study (numbers in brackets indicate dead animals in group): 10 (0) (No-MCT), 10 (0) (MCT+Veh), 9 (1) (RP), 8 (2) (B), 10 (0) (B+RP), 10 (0) (S), 9 (1) (S+RP), 9 (1) (T), and 9 (1) (T+RP). The rate of deaths observed in this study was consistent with the historical mortality rate at the IPST facility.
Systemic hemodynamic and cardiac parameters (Day 28)
Table 1 summarizes the systemic hemodynamic and cardiac parameters at the time of surgery. As compared with the No-MCT group, the MCT+Veh group displayed significantly lower pulse pressure (PP) and higher SAP Syst (P < 0.05). As compared with the MCT+Veh group, treatments showed mixed effects depending on the parameter. RP showed significant differences (P < 0.05) across all parameters, particularly with B and T. With respect to co-administration, RP showed higher PP and SAP Diast measurements (P < 0.05).
Pulmonary hemodynamic parameters (Day 28)
Fig. 1 illustrates pulmonary hemodynamic parameters at surgery for mean pulmonary pressure (mPAP) and systolic ventricular pressure (RVSP). The MCT+Veh group showed increases in each of these parameters (P < 0.001).
Animals who were treated with RP, alone or as co-administered with B, S, and T, demonstrated significant reductions in all pulmonary hemodynamic parameters, as compared with those treated MCT+Veh (P < 0.01). The most robust effects were observed with S+RP. These were consistently the largest across all parameters. B, S, and T as monotherapy were inconsistent in their relative effects, as compared with MCT+Veh, depending on the pulmonary parameter measured. For mPAP, all treatments except for T showed significance (P < 0.05), as compared with MCT+Veh. For PAP Diast , only RP, B+RP, S, and S+RP displayed significance, as compared with MCT+Veh (P < 0.01). With respect to RVSP, all treatments except for B significantly (P < 0.01) improved this parameter.
As an adjunct to B and S, RP treatment showed significantly lower diastolic pulmonary artery pressure, as compared with single-agent monotherapy, when adjusting for multiplicity using the Bonferroni method (P < 0.05 and 0.01, respectively). Adjunctive therapy of RP with T did show lower or comparable RV systolic pressure, systolic pulmonary artery pressure (NS). Fig. 2 highlights the respiratory parameters of the animals at the time of surgery, including oxygen saturation (SO 2 ), respiratory resistance, and ventilatory pressure (VP). The MCT+Veh group showed a reduction in SO 2 (P < 0.001) and an increase in respiratory resistance of (P < 0.01). All treatments improved SO 2 , as compared with MCT+Veh, but were inconsistent in their effects on respiratory resistance and ventilatory pressure. Mean respiratory resistance and ventilator pressure values of RP and S appeared to be either lower or similar than mean B, B+RP, and T values, but were not significant.
The MCT+Veh group showed an increased Fulton's index (as a Fig. 1 . Effect of treatment on pulmonary hemodynamic parameters of MCT-induced PAH rats at time of surgery (Day 28). Panels A-B illustrate the effect on mPAP (A) and on the RVSP (B). * P < 0.05, ** P < 0.01, *** P < 0.001; as compared to No-MCT. # P < .05, ## P < 0.01, ### P < 0.001; as compared to MCT+Veh. Combined treatment were compared with respective base single-agent therapy using one-way ANOVA with Bonferroni multiplicity adjustment. B-Bosentan, 100 mg/kg b.i. reflection of RV hypertrophy) (P < 0.0001). Treatment with RP, S, and S+RP significantly (P < 0.05) limited this increase in the Fulton index. Table 2 depicts body temperature, weight gain, and relative lung, liver, and trachea weights. The MCT+Veh group showed significant differences from the No-MCT group with respect to weight gain, (P < 0.0001), body temperature (P < 0.001), and lung weight (P < 0.0001). Only the T+RP group showed a significant decrease in lung weight (P < 0.001). Table 3 and Fig. 3A highlight the effect of treatment on the percentage of muscular vessels, semi-muscular vessels, and non-muscular vessels. As compared with the No-MCT group, the MCT+Veh showed a higher percentage of muscular vessels and a lower percentage of nonmuscular tissue (P < 0.001). All treatments produced a lower percentage of muscular tissue and higher percentage of non-muscular tissue when compared with MCT+Veh (P < 0.0001 for both). Fig. 3B illustrates the effect of treatment on vessel wall thickness. Wall thicknesses were greater in the MCT+Veh group versus the No-MCT induced group for small, medium, and large vessels (P < 0.01). All treatments provided significant reductions of small vessels, (P < 0.05). With respect to medium vessel size, only S showed a significant impact on medium vessel size with (P < 0.0001).
Systemic parameters
Histologic findings
Discussion
MCT-induced PAH
The MCT rat model is widely-used to study idiopathic PAH in rodents (Gomez-Arroyo et al., 2016; Stenmark et al., 2009; Zopf et al., 2011) . In this study, the MCT-treated animals developed PAH, with significant hemodynamic, respiratory, systemic, and histologic changes, as compared to the MCT+veh group. RP significantly lowered mPAP and RVSP induced by MCT. These observations may indicate that treatment helped to reduce the load on the RV, which was further supported by a return to normal HR and reduced Fulton's index. The latter strongly suggests that RV hypertrophy was mitigated. Its effect on systemic PP suggests that RP allowed the heart to maintain its stroke volume and helped normalize SO 2 . Lack of structural change suggests that RP prevented pulmonary vasculature remodeling.
These findings confirm previous observations (Bhat et al., 2017a; Bhat et al., 2017b) . In the MCT model, RP at 10 mg/kg b.i.d significantly reduced pulmonary hemodynamic, respiratory, and histologic parameters, and blocked increases in tumor necrosis factor α (TNF-α), interleukin (IL) 1β, and IL-6 (Bhat et al., 2017a) . In the SuHxinduced model, RP at 10-and 20-mg/kg b.i.d. significantly reduced PAP Syst , lowered the percentage of muscular vessels, and prevented the release of LT-B4 (Bhat et al., 2017b) . The 10-mg/kg dose reduced RVSP and normalized SO 2, while the 20-mg/kg dose significantly reduced small-vessel wall thickness.
Bosentan, sildenafil, and treprostinil therapy
Current US Food and Drug Administration-approved PAH treatment involves 3 standard agents-B, S, and T-which served as reference comparators. All primarily address smooth muscle tone to improve vasodilation and improve hemodynamics.
S produced the most consistent effects on all hemodynamic and respiratory parameters. As a vasodilator, S showed improvements over the MCT control on pulmonary hemodynamics and respiratory effects. These effects translated to a decreased Fulton's index, normalized SO 2 , and increased body temperature. The effect of S on the pulmonary arteries, which led to a reduced proportion of muscular vessels, increased proportion of non-muscular vessels, and reduced small-and mediumsized vessels. These observations suggest that vasodilation drives the effect of S in PAH remodeling.
B and T affected several parameters, though not as robust as those seen with RP or S. The effects of these 2 treatments appeared to be mediated by the prevention of vascular constriction early in the hypoxic development of the disease, culminating in less vascular smooth muscle remodeling. LGW, Lung weight; TW, relative tracheal weight; S.E.M., standard error of the mean; WG, weight gain. a P < 0.01; as compared to No-MCT, Control animals no MCT. b P < 0.001; as compared to MCT+Veh, MCT-induced rats. c P < 0.05; as compared with base single-agent therapy using one-way ANOVA with Bonferroni multiplicity adjustment. Comparatively, RP showed numerical trends versus these treatments: 1) higher body temperatures versus all groups; 2) lower PAP Diast , RR, and VP, as compared with B; 3) greater gains in body weight over the B and S groups; 4) lower mPAP and VP, as compared with T; and 4) Lower lung weight and reduced small and medium pulmonary arteriole vessel thickness to a lesser degree relative to S.
When co-administered with B, S, and T, RP improved respiratory and histologic parameters, as compared with MCT+Veh. The RP+S combination showed the most consistent and extensive effects of pulmonary hemodynamics and respiratory parameters. As compared with single-agent therapy, addition of RP displayed trends towards improvement and significance with selected parameters.
Underlying rationale for RP5063 effectiveness
These findings, along with those from prior studies, indicate that RP provides both functional and structural effects relevant to idiopathic PAH management (Bhat et al., 2017a (Bhat et al., , 2017b . Underlying is the pathologic role that 5-HT plays in the proliferative and functional components of PAH (West et al., 2016; Esteve et al., 2007; MacLean and Dempsie, 2010) . Pulmonary arteries express 5-HT 1B/2A/2B/7 receptors (Shacham et al., 2006) . Synthesis of 5-HT outside of the central nervous system occurs in the endothelial cells of the pulmonary artery (Sirek and Sirek, 1970) . 5-HT is a mitogen of human and rat pulmonary endothelial and smooth muscle tissue (Esteve et al., 2007) . Its presence in the pulmonary circulation activates 5-HT 2A/2B receptors and SERT causing pulmonary VSM constriction and cell proliferation (Dumitrascu et al., 2011; Zopf et al., 2011) .
RP is a multimodal D-5-HT stabilizer. While D 2/3/4 activity on the pulmonary vascular tissue is unclear, the effects of RP are mediated through moderate affinity for SERT and high affinity for 5-HT 2A/2B/7 receptors (Cantillon et al., 2017) . The interference of 5-HT 2A signaling prevents vasoconstriction directly in the pulmonary vasculature, translating to significant improvements in pulmonary hemodynamic and respiratory parameters (Dumitrascu et al., 2011; Farber and Loscalzo, 2004) . When blocking 5-HT 2B signaling, the mitigation of cell proliferation and vascular remodeling resulted in structural changes observed in the pulmonary vasculature and lower lung weight (Dumitrascu et al., 2011; Farber and Loscalzo, 2004) . The anti-proliferative effects of RP are potent.
Furthermore, RP appears to affect the release of inflammatory cytokines and chemokines. In the previous MCT-induced study, RP resulted in lower levels of the IL-1β, IL-6, and TNF-α, as compared to MCT+Veh (Bhat et al., 2017a) . This observation provides useful insight, because inflammatory cytokines play a critical role in the development of PAH, the proliferation of vascular cells, and the remodeling of the pulmonary arteries (Humbert et al., 1995; Itoh et al., 2006; Prince et al., 2012; Soon et al., 2010) . In the SuHx-induced model, RP limited the LT-B4, a mediator of pulmonary inflammation and contributor to pulmonary vascular remodeling (Bhat et al., 2017b; Tian et al., 2014) .
Single-agent RP appeared comparable with the current treatment standards. As an adjunct, RP added numerically to the functional and structural benefits of single-agent therapy, most notably with S. The basis for these observations might be related to the distinct mechanisms of action of these agents. S acts by inhibiting phosphodiesterase 5 to cause direct pulmonary VSM relaxation and vasodilation, without directly preventing vascular remodeling (Barnett and Machado, 2006) , whereas RP contributes a complementary benefit through its 5-HT 2A/2B/ 7 signaling and chemokine/cytokine-reduction effects. Adding RP offered some improvement to T, a direct vasodilator. The addition of RP to B produced the least consistent and pronounced effects; this observation might be due to the overlap in the mechanisms of action of the 2 drugs, with B mitigating the effect of elevated endothelin 1, which can stimulate VSM proliferation (Lai et al., 2014; Régent et al., 2017) .
Study limitations
Consistent with past studies, this study was powered at 10 rats per group to discern differences, as compared with the MCT-induced control (Bhat et al., 2017a (Bhat et al., , 2017b . It was not designed to compare individual treatments or single-agent therapy with these individual treatments and RP. Use of a one-way ANOVA with Bonferroni multiplicity adjustment evaluated significance. While RP therapy as an adjunct showed significance in selected parameters and trends towards significance among others, the ability to determine significance was limited by the delta between treatments, treatment group variability, and the individual group sample size. Future studies should consider these issues when determining sample size.
The lack of a sham MCT+control group for the AZLET pump infusion, used to continuously infuse T throughout the 28-day period, was another consideration. While T displayed significance in several functional parameters, as compared to the MCT+control, its effects as a single-agent and when combined with RP were the least robust of all treatments. The inclusion of a pump infusion could have introduced a confounding influence. Future studies should include a sham comparator group to accommodate for the difference in route and timing of drug administration.
A final limitation involved the sole use of catherization to measure hemodynamic parameters and cardiac function. However, the primary goal of this study was to characterize the effect of treatment on PAH by comparing hemodynamic function rather than focusing on the resulting consequence that impact cardiac function. In this study, the catheter was placed directly in the pulmonary artery measuring PAP Diast and PAP Syst in order to provide a direct indication of the pulmonary artery tone. This methodology went further than most publications in measuring vascular tone by pushing the catheter all the way up in the pulmonary artery rather than leaving it in the right ventricle (Abe et al., 2010) . This methodology has been established in this model of PAH, including the 2 published studies with RP (Abe et al., 2010; Bhat et al., 2017a Bhat et al., , 2017b Janssen et al., 2015 , Porvasnik et al., 2010 Schreiber et al., 2017; Zhang et al., 2017; Zopf et al., 2011; Otsuki et al., 2015) . Furthermore, the RV hypertrophy measured by the increased ratio of the Fulton's index has been largely associated with RV dilation in this PAH model (Ryan et al., 2015; Ryan et al., 2014) . It was a limitation not to confirm the RV end-diastolic and end-systolic volumes by echocardiography. Stroke volume and cardiac output, indicative of cardiac function, are usually altered in this model due to the increased PAP and RV dilation. The improved PAP involved with RP provided evidence that this approach would reduce cardiac function burden leading to heart failure. It should be noted that no conclusions were based on the pulmonary vascular resistance per se, but rather on the PAP, specifically PAP Diast , improvements. Overall, these methods appear to be robust and consistent with published literature; future studies might incorporate doppler-based measurements.
Conclusions
This study demonstrated that single-agent and co-administered RP reduced PAH in a MCT-induced rat model that mimics idiopathic PAH in humans. As a single-agent, RP at 10 mg/kg b.i.d. was statistically efficacious in limiting the functional and structural effects of PAH induced by MCT. As an individual treatment, the effects of RP appeared comparable with those seen with B, S, and T. Furthermore, RP displayed preliminary evidence of being an effective adjunct to B, S, and T. Its effects with S appeared to the most consistent and extensive. This finding might be of clinical importance, as greater than 50% of patients with PAH will be on an additional treatment co-administered with the original therapy within 2 years of the PAH diagnosis (Provencher et al., 2006) .
Combined, these findings corroborate and build upon previous preclinical work evaluating the efficacy of RP in PAH, as compared with the induced-control (Bhat et al., 2017a (Bhat et al., , 2017b . These results suggest that combinations of vasodilators and anti-proliferative agents could offer the potential of being disease-modifying. These observations need further exploration in both the preclinical and clinical settings to identify the optimal strategy for adjunctive therapy that involves RP.
